It has been achieved through a genetic test, determine the response of children suffering from a type of leukemia called acute lymphoblastic. In this way, the pharmacological treatment for each child can be customized and thus avoid the toxicity to which they are exposed when they perform the treatment against leukemia of this type, the response by the child will be much more positive.
Thanks to pharmacogenetics, genetic-based diseases can be detected early, improving treatments by adapting them to the genetic profile of the patient and achieving fewer side effects. Individualized medicine is a fact, this reminds us, for example, of nutrigenomics (personalized diets at the genetic level). The more personalized a treatment, the better the response from the organism, it must be understood that each organism is different and each one has its individual needs. The new pilot program for the use of pharmacogenetics in the treatment of acute lymphoblastic in children, is based on the application of a genetic test, thus getting to know how the organism will act against the treatment. This will avoid "mistakes" when using one treatment or another, in addition to administering the appropriate doses.
